FDA Addresses the New Guidances at the 10th REMS Summit
Tuesday December 5th, 2017
Since the release of ExL Events‘ 10th REMS Summit brochure, the FDA has released two guidances that amplify your need to attend the event that has every REMS professional talking. In light of these changes, we are excited to announce the expansion of the 10th Annual REMS Summit program to address the evolving REMS landscape!
TWO BRAND-NEW SESSIONS ADDED!
OVERVIEW OF RECENT FDA GUIDANCES IMPACTING REMS
Gita Toyserkani, Pharm.D., MBA, Regulatory Health Policy Analyst, Division of Risk Management, Office of Medication Error Prevention and Risk Management, Office of Surveillance and Epidemiology, FOOD AND DRUG ADMINISTRATION
Suzanne Robottom, Pharm.D., Regulatory Health Policy Analyst, Division of Risk Management, Office of Medication Error Prevention and Risk Management, Office of Surveillance and Epidemiology, FOOD AND DRUG ADMINISTRATION
HOT OFF THE PRESS: NEW FDA INITIATIVES AND GUIDELINES
Annette Stemhagen, MPH, DrPH, Senior Vice President, Safety, Epidemiology, Registries and Risk Management, UNITED BIOSOURCE CORPORATION
Click here to see the fully updated agenda.
Thirty other speakers representing pharmaceutical companies, health systems, and regulatory agencies join Gita, Suzanne, and Annette on the 10th Annual REMS Summit speaking faculty. Connect with and learn from your industry peers at the REMS Summit on January 29–30 in Arlington, VA.
Click here to register today and mention Discount Code C988BLOG for 15% off standard registration!
From The Blog
- Commercial Strategy
- Content Marketing
- Data Management
- Digital Marketing
- Drug Safety
- Emerging Markets
- ExL Events News
- Medical Devices
- Medical Education
- Meeting Planning
- Patient Engagement
- Public/Government Relations
- Regulatory Affairs